Xianhai Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7543251/publications.pdf

Version: 2024-02-01

840776 794594 19 362 11 19 citations h-index g-index papers 22 22 22 385 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Generation of Leads for Î ³ -Secretase Modulation. Journal of Medicinal Chemistry, 2020, 63, 8216-8230.	6.4	7
2	Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma. ACS Medicinal Chemistry Letters, 2018, 9, 679-684.	2.8	10
3	Discovery of a Tetrahydrobenzisoxazole Series of \hat{I}^3 -Secretase Modulators. ACS Medicinal Chemistry Letters, 2017, 8, 1002-1006.	2.8	9
4	The synthesis of 2,3,6-trisubstituted 1-oxo-1,2-dihydroisoquinolines as potent CRTh 2 antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5344-5348.	2.2	6
5	The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 466-471.	2.2	23
6	Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3262-3266.	2.2	20
7	Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 100-105.	2.8	13
8	Efficient and regioselective synthesis of pyrimido [5,4-d] pyrimidine-2,4,6,8 (1H,3H,5H,7H)-tetraones with diversified substitutions. Tetrahedron Letters, 2012, 53, 7154-7158.	1.4	10
9	Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. Tetrahedron Letters, 2012, 53, 6451-6455.	1.4	8
10	A Case Study of Singleâ€Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia. ChemMedChem, 2012, 7, 1882-1894.	3.2	5
11	Synthesis and SAR Studies of Fused Oxadiazines as î³-Secretase Modulators for Treatment of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2012, 3, 931-935.	2.8	34
12	Cyclic Hydroxyamidines as Amide Isosteres: Discovery of Oxadiazolines and Oxadiazines as Potent and Highly Efficacious Î ³ -Secretase Modulators in Vivo. Journal of Medicinal Chemistry, 2012, 55, 489-502.	6.4	52
13	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters, 2012, 3, 63-68.	2.8	22
14	A three-step protocol for lead optimization: Quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 65-70.	2.2	20
15	SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 854-858.	2.2	12
16	Discovery of a Potent Pyrazolopyridine Series of \hat{I}^3 -Secretase Modulators. ACS Medicinal Chemistry Letters, 2011, 2, 471-476.	2.8	33
17	Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters, 2011, 2, 171-176.	2.8	20
18	Discovery of fused 5,6-bicyclic heterocycles as \hat{I}^3 -secretase modulators. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 664-669.	2.2	26

#	Article	IF	CITATIONS
19	The Discovery of Pyridone and Pyridazone Heterocycles as Î ³ -Secretase Modulators. ACS Medicinal Chemistry Letters, 2010, 1, 184-187.	2.8	32